Event context and recent stock performance

Tarsus Pharmaceuticals (TARS) has attracted investor attention recently as its share price has moved over the past month and past 3 months, with the stock last closing at US$63.96 and a market value of about US$2.8b.

Zooming out, the stock’s recent share price returns, including a 6.98% 1 month decline and a 20.81% year to date decline, contrast with a 35.68% 1 year total shareholder return and very large 3 year total shareholder return. This suggests that longer term momentum has been strong even as near term sentiment has cooled.

If you are looking beyond Tarsus Pharmaceuticals, this could be a good moment to broaden your search with 35 healthcare AI stocks

With Tarsus Pharmaceuticals posting rapid reported revenue and net income growth alongside recent share price weakness, is the current valuation still conservative or is the market already factoring in much of the company’s future potential?

Most Popular Narrative: 32.8% Undervalued

Based on the most followed narrative, Tarsus Pharmaceuticals’ fair value of about $95.11 sits well above the last close at $63.96, and that gap rests on some very specific growth and margin expectations.

The company's pipeline expansion (e.g., TP-04 for ocular rosacea) positions Tarsus for multi-product leverage in underserved markets, supporting diversified, long-term earnings growth and reducing future revenue concentration risk.

This raises questions about the kind of revenue ramp, margin shift, and valuation multiple that are being factored into that fair value. The narrative refers to compound growth, rising profitability, and a richer P/E than the wider US pharmaceuticals sector to support its view. The full breakdown details how those elements are combined into a discounted cash flow style framework at a 6.98% discount rate, and how that leads to a fair value that is presented as comfortably above today’s share price.

Result: Fair Value of $95.11 (UNDERVALUED)

However, this outlook still hinges on XDEMVY sustaining strong uptake, and on high SG&A and reimbursement pressures not capping the margin expansion analysts are baking in.

Next Steps

With such mixed signals on valuation and sentiment, do you feel the stock is being priced fairly right now, or not yet? Take a moment to review both sides of the story for yourself with 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Tarsus Pharmaceuticals is on your radar, do not stop there. A wider watchlist gives you more chances to spot opportunities that match your approach.

• Target reliable cash generators by scanning for companies with resilient finances using the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for potential bargains by checking stocks that screen as attractively priced with the 51 high quality undervalued stocks.
• Prioritize resilience by focusing on companies that carry lower risk scores through the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.